Aktieanalys

Egetis Q4 2022: Initial comment - Redeye

Redeye Publicerad: 22 Feb 2023 09:05

Redeye notes that Egetis’ Q4 report presented SEK5.7m in revenues and SEK-83.9m in operating expenses, which closely correspond to our forecasts, albeit with a somewhat larger increase in OPEX than anticipated. This outcome indicates a stable business operation and the continued implementation of a commercial structure to prepare for the Emcitate launch. It is worth mentioning that the estimated timelines for regulatory submission with Emcitate (now scheduled for H2 2023) and study commencement with Aladote (now 2023) have been extended somewhat. At present, we do not foresee any significant adjustments to our valuation and will soon return with a more extensive take.

Länk till analysen i sin helhet: https://www.redeye.se/research/882258/egetis-q4-2022-initial-comment?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!